ReviewCell communication and signaling : CCS2025
TDP-43: unveiling the hidden key to cellular fate decisions.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative Analysis of Plasma Biomarkers of Alzheimer's Disease and Frontotemporal Dementia: The Dual Role of Soluble Fractalkine as a Biomarker of Frontotemporal Dementia and Its Neuroprotective Effects in Cortical Neurons "In Vitro".Life (Basel, Switzerland) · 2026Article
- Distinct single-nucleus RNA-seq changes among non-neuronal cells in ADNC, LATE-NC, and mixed pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Artificial intelligence-based 3D segmentation of tangle-associated TDP-43 in neurodegeneration.Brain pathology (Zurich, Switzerland) · 2026Article
- Elevated TARDBP expression correlates with an unfavorable prognosis, immune evasion, and poor immune efficacy in hepatocellular carcinoma.Translational cancer research · 2026Article
- TDP-43 Aggregation: The Healthy-Toxic Balance of the Prion-Like Domain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
TDP-43, a multifaceted RNA-binding protein (RBP), has emerged as a key regulator in neurodegenerative diseases. Yet, its underlying mechanisms of action across other diseases remain unclear. This review covers TDP-43’s structural domains, its pathology in neurodegenerative diseases, and its liquid-liquid phase separation (LLPS) properties, where the disease pathology and LLPS together drive its aggregate-forming behavior. This review then focuses on the nucleocytoplasmic shuttling mechanisms of TDP-43, analyzing their role in governing its subcellular localization and functional diversity. The review further summarizes how TDP-43 modulates cellular metabolism (encompassing lipid, glucose, and ATP homeostasis) and cell death pathways in neurological disorders, cancer, and immunity. Finally, this review highlights unresolved questions, including the putative role of TDP-43 as an RBP in post-transcriptional RNA modification and the regulatory networks controlling its expression, thereby providing directions for clinical diagnosis and treatment of TDP-43-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.